PURPOSE: Metastatic breast cancer is devastating and triple negative breast cancers (TNBC) have a higher propensity for metastasis. Improved local control upfront in this aggressive cancer could potentially decrease its propensity toward metastasis. We sought to determine if using caloric restriction (CR) as a systemic therapy, combined with radiation therapy (IR) to the primary tumor, may impact metastatic disease. METHODS: An orthotopic mouse model using a highly metastatic, luciferase-tagged TNBC cell line (4T1), was used to generate palpable tumors. Mice were then treated with CR, IR, and a combination of the two. In vivo imaging was performed for metastatic evaluation. Molecular evaluation of the tumors was performed, generating a mechanistic hypothesis for CR, which was then tested with pertinent pathway inhibition in the model. RESULTS: CR significantly increased the time to developing metastases, decreased the overall number and volume of lung metastases, and increased survival. CR decreased proliferation, increased apoptosis and globally downregulated the IGF-1R signaling pathway. Adding an IGF-1R/INSR inhibitor to local IR in vivo accomplished a decrease in metastases similar to CR plus IR, demonstrating the importance of the IGF-1R signaling pathway, and underscoring it as a possible mechanism for CR. CONCLUSIONS: CR decreased metastatic burden and therefore may complement cytotoxic therapies being used in the clinical setting for metastatic disease. Downregulation of the IGF-1R pathway, is in part responsible for this response and modulating IGF-1R directly resulted in similar improved progression-free survival. The novel use of CR has the potential to enhance clinical outcomes for patients with metastatic breast cancer.
PURPOSE: Metastatic breast cancer is devastating and triple negative breast cancers (TNBC) have a higher propensity for metastasis. Improved local control upfront in this aggressive cancer could potentially decrease its propensity toward metastasis. We sought to determine if using caloric restriction (CR) as a systemic therapy, combined with radiation therapy (IR) to the primary tumor, may impact metastatic disease. METHODS: An orthotopic mouse model using a highly metastatic, luciferase-tagged TNBC cell line (4T1), was used to generate palpable tumors. Mice were then treated with CR, IR, and a combination of the two. In vivo imaging was performed for metastatic evaluation. Molecular evaluation of the tumors was performed, generating a mechanistic hypothesis for CR, which was then tested with pertinent pathway inhibition in the model. RESULTS: CR significantly increased the time to developing metastases, decreased the overall number and volume of lung metastases, and increased survival. CR decreased proliferation, increased apoptosis and globally downregulated the IGF-1R signaling pathway. Adding an IGF-1R/INSR inhibitor to local IR in vivo accomplished a decrease in metastases similar to CR plus IR, demonstrating the importance of the IGF-1R signaling pathway, and underscoring it as a possible mechanism for CR. CONCLUSIONS: CR decreased metastatic burden and therefore may complement cytotoxic therapies being used in the clinical setting for metastatic disease. Downregulation of the IGF-1R pathway, is in part responsible for this response and modulating IGF-1R directly resulted in similar improved progression-free survival. The novel use of CR has the potential to enhance clinical outcomes for patients with metastatic breast cancer.
Entities:
Keywords:
Caloric restriction; breast cancer; metastases
Authors: Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol Journal: J Clin Invest Date: 2011-07 Impact factor: 14.808
Authors: Joan M Carboni; Mark Wittman; Zheng Yang; Francis Lee; Ann Greer; Warren Hurlburt; Stephen Hillerman; Carolyn Cao; Glenn H Cantor; Janet Dell-John; Cliff Chen; Lorell Discenza; Krista Menard; Aixin Li; George Trainor; Dolatrai Vyas; Robert Kramer; Ricardo M Attar; Marco M Gottardis Journal: Mol Cancer Ther Date: 2009-12 Impact factor: 6.261
Authors: M Gryko; J Kiśluk; D Cepowicz; J Zińczuk; Z Kamocki; K Guzińska-Ustymowicz; A Pryczynicz; J Czyżewska; A Kemona; B Kędra Journal: Pol J Pathol Date: 2014-06 Impact factor: 1.072
Authors: James B Mitchell; Rajani Choudhuri; Kristin Fabre; Anastasia L Sowers; Deborah Citrin; Sonya D Zabludoff; John A Cook Journal: Clin Cancer Res Date: 2010-03-16 Impact factor: 12.531
Authors: Paul Haluska; Heather M Shaw; Gretchen N Batzel; Donghua Yin; Julian R Molina; L Rhoda Molife; Timothy A Yap; M Luisa Roberts; Amarnath Sharma; Antonio Gualberto; Alex A Adjei; Johann S de Bono Journal: Clin Cancer Res Date: 2007-10-01 Impact factor: 12.531
Authors: Heather M McGee; Dadi Jiang; David R Soto-Pantoja; Avinoam Nevler; Amato J Giaccia; Wendy A Woodward Journal: Clin Cancer Res Date: 2019-02-05 Impact factor: 12.531
Authors: Giulia Petroni; Lewis C Cantley; Laura Santambrogio; Silvia C Formenti; Lorenzo Galluzzi Journal: Nat Rev Clin Oncol Date: 2021-11-24 Impact factor: 66.675
Authors: Oliver Kepp; Lucillia Bezu; Takahiro Yamazaki; Francesco Di Virgilio; Mark J Smyth; Guido Kroemer; Lorenzo Galluzzi Journal: EMBO J Date: 2021-06-14 Impact factor: 14.012